GlaxoSmithKline PLC ADR

GSK develops and sells vaccines for diseases like RSV, shingles, flu, and HPV, plus specialty treatments for cancer, HIV, and respiratory conditions, and everyday medicines for asthma and infections [COMPANY OVERVIEW]. The company operates globally with manufacturing and research facilities, selling through hospitals, clinics, and pharmacies in over 100 countries. GSK also collaborates with partners like CureVac on mRNA vaccine technology and AN2 Therapeutics on tuberculosis therapies [COMPANY OVERVIEW].

GSK is a major UK-headquartered pharmaceutical company that makes vaccines (RSV, flu, shingles, meningitis), specialty medicines (oncology, HIV, respiratory), and general medicines (asthma, COPD, antibiotics) [COMPANY OVERVIEW]. With $32.7 billion in revenue and a 17.5% net margin, the company is financially healthy and generates $5.8 billion in free cash flow annually [Yahoo Finance]. Recent news shows Japan expanded approval for GSK's RSV vaccine Arexvy to younger at-risk adults, opening a larger market [Nasdaq].

GSK is financially strong with solid profitability, low debt, and healthy cash generation.